Bristol Myers: EPS down 2% in Q4

(CercleFinance.com) - Bristol Myers Squibb reports adjusted EPS for the last three months of 2024 down 2% to $1.
67, with a non-GAAP gross margin down 2.4 points to 74%, mainly due to its product mix. NB: pmt -5.3%.

The pharmaceutical company's revenues grew by 8% to over $12.3bn (+9% excluding currency effects), supported mainly by its growth portfolio and higher demand for Eliquis.

For 2025, Bristol Myers anticipates adjusted EPS of between $6.55 and $6.85, and revenues of around $45.5bn, compared with adjusted EPS of $1.15 and revenues of $48.3bn for the past year.


Copyright (c) 2025 CercleFinance.com. All rights reserved.